Sugi Predict

Sugi Predict / Compounds / SCHEMBL10140211

SCHEMBL10140211

SCHEMBL10140211

NNC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12

nearest known ligand 0.71

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 5/20 0.71
▸ MEN1 O00255 1/20 0.71
▸ ABL1 P00519 1/20 0.71
▸ LMNA P02545 1/20 0.71
▸ PKM P14618 1/20 0.71
▸ IDE P14735 1/20 0.71
▸ MAPK1 P28482 1/20 0.71
▸ KMT2A Q03164 1/20 0.71
▸ RIN1 Q13671 1/20 0.71
▸ L3MBTL1 Q9Y468 1/20 0.71
▸ CA12 O43570 6/20 0.63
▸ CA1 P00915 6/20 0.63
▸ CA2 P00918 6/20 0.63
▸ CA9 Q16790 6/20 0.63
▸ HLCS P50747 6/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL565406 1.00 TDP1 (0.71) TDP1MEN1ABL1LMNAPKM
SCHEMBL5585656 1.00 TDP1 (0.71) TDP1MEN1ABL1LMNAPKM
SCHEMBL12424056 1.00 TDP1 (0.71) TDP1MEN1ABL1LMNAPKM
SCHEMBL19514780 1.00 TDP1 (0.71) TDP1MEN1ABL1LMNAPKM
SCHEMBL33865 1.00 TDP1 (0.71) TDP1MEN1ABL1LMNAPKM
SCHEMBL5585660 1.00 TDP1 (0.71) TDP1MEN1ABL1LMNAPKM
SCHEMBL14812382 0.99 TDP1 (0.70) TDP1MEN1ABL1LMNAPKM
Hydrazine SCHEMBL28140320 0.99 TDP1 (0.70) TDP1MEN1ABL1LMNAPKM
SCHEMBL23863708 0.96 TDP1 (0.65) TDP1MEN1ABL1LMNAPKM
SCHEMBL1024507 0.94 HLCS (0.72) TDP1MEN1ABL1LMNAPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260137621-A1 ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS DIASOME PHARMACEUTICALS INC (US) 2026-05-21 — — US disclosed
US-20260124139-A1 LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL DIASOME PHARMACEUTICALS INC (US) 2026-05-07 — — US disclosed
US-20250288521-A1 ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS DIASOME PHARMACEUTICALS INC (US) 2025-09-18 — — US disclosed
EP-2552202-B1 METHODS AND COMPOSITIONS FOR WEIGHT LOSS SDG INC (US) 2023-07-26 — — EP disclosed
EP-2552202-B1 METHODS AND COMPOSITIONS FOR WEIGHT LOSS SDG INC (US) 2023-07-26 — — EP disclosed
US-11517529-B2 Orally bioavailable lipid-based constructs SDG, INC. (US) 2022-12-06 — — US disclosed
US-11517529-B2 Orally bioavailable lipid-based constructs SDG, INC. (US) 2022-12-06 — — US disclosed
US-20220110870-A1 LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL SDG INC (US) 2022-04-14 — — US disclosed
EP-3391876-B1 LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL SDG INC (US) 2021-03-10 — — EP disclosed
EP-3391876-B1 LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL SDG INC (US) 2021-03-10 — — EP disclosed
US-20100247625-A1 Orally Bioavailable Lipid-Based Constructs SDG, INC. 2010-09-30 — — US disclosed
US-20100247625-A1 Orally Bioavailable Lipid-Based Constructs SDG, INC. 2010-09-30 — — US disclosed
US-20100129428-A1 SUPRA MOLECULAR CONSTRUCT FOR DELIVERY OF INTERFERON TO A MAMMAL SDG, INC. 2010-05-27 — — US disclosed
US-20100129428-A1 SUPRA MOLECULAR CONSTRUCT FOR DELIVERY OF INTERFERON TO A MAMMAL SDG, INC. 2010-05-27 — — US disclosed
US-20100080773-A1 Orally Bioavailable Lipid-Based Constructs SDG, INC. 2010-04-01 — — US disclosed
US-20100080773-A1 Orally Bioavailable Lipid-Based Constructs SDG, INC. 2010-04-01 — — US disclosed
US-20090087479-A1 Orally bioavailable lipid-based constructs SDG, INC. ( AN OHIO CORPORATION) (US) 2009-04-02 — — US disclosed
US-20090087479-A1 Orally bioavailable lipid-based constructs SDG, INC. ( AN OHIO CORPORATION) (US) 2009-04-02 — — US disclosed
US-20070218117-A1 Supra molecular construct for delivery of interferon to a mammal SDG, INC. 2007-09-20 — — US disclosed
US-20070218117-A1 Supra molecular construct for delivery of interferon to a mammal SDG, INC. 2007-09-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070218117-A1 Supra molecular construct for delivery of interferon to a mammal HAVCR2, IFNAR1, MSR1 TDP1 4728/4885MEN1 4097/4885ABL1 2979/4885
US-20100080773-A1 Orally Bioavailable Lipid-Based Constructs FABP2, FABP1, LIPC TDP1 4742/4885MEN1 1477/4885ABL1 3308/4885
US-20100129428-A1 SUPRA MOLECULAR CONSTRUCT FOR DELIVERY OF INTERFERON TO A MAMMAL HAVCR2, IFNAR1, IFNG TDP1 4713/4885MEN1 4095/4885ABL1 2883/4885
US-20250288521-A1 ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS FABP2, FABP1, FABP6 TDP1 4819/4885MEN1 966/4885ABL1 4375/4885
US-20260137621-A1 ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS FABP2, FABP1, SGMS2 TDP1 4755/4885MEN1 2415/4885ABL1 4626/4885
US-20220110870-A1 LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL INSR, IAPP, GPR119 TDP1 4882/4885MEN1 1400/4885ABL1 3769/4885
US-20260124139-A1 LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL GPR119, INSR, FABP1 TDP1 4833/4885MEN1 2073/4885ABL1 4576/4885
US-11517529-B2 Orally bioavailable lipid-based constructs FABP2, FABP1, FABP6 TDP1 4819/4885MEN1 966/4885ABL1 4375/4885
US-20090087479-A1 Orally bioavailable lipid-based constructs FABP2, FABP1, FABP6 TDP1 4757/4885MEN1 1343/4885ABL1 3225/4885
US-20100247625-A1 Orally Bioavailable Lipid-Based Constructs FABP2, LIPC, FABP6 TDP1 4650/4885MEN1 1077/4885ABL1 3190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.